LARGE B-CELL LYMPHOMA
Clinical trials for LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cell therapy shows promise for hard-to-treat blood cancers
Disease control OngoingThis study tests a new treatment called rapcabtagene autoleucel (YTB323) for adults with several types of blood cancer, including chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. The treatment uses a patien…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 07:11 UTC
-
New drug cocktail offers hope for lymphoma patients who have run out of options
Disease control OngoingThis study tests a combination of two drugs, tafasitamab and lenalidomide, in adults with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to previous treatments. Participants must have had 1 to 3 prior treatments and cannot have a s…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 26, 2026 07:08 UTC
-
New CAR t therapy shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis early-phase study tests a new treatment called SC262 for people with Non-Hodgkin's lymphoma that has come back or not responded to other therapies. SC262 is a type of immune cell therapy (CAR T) made from donor cells, designed to target cancer cells. The main goal is to chec…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated May 26, 2026 07:05 UTC
-
Immune cells from donors show promise against Hard-to-Treat blood cancers
Disease control OngoingThis early-phase study tests NKX019, a therapy made from donor immune cells (natural killer cells) that are engineered to find and attack cancer cells. It is for adults with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to other treatments…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated May 26, 2026 06:58 UTC
-
New CAR T-Cell therapy shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests a new type of CAR T-cell therapy for adults with B-cell lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to better target and kill cancer cells. The main goals are to find the safest dose and see i…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New combo therapy shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis early-phase study tests whether adding the drug mosunetuzumab to standard chemotherapy is safe and effective for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. About 24 participants will receive one of two chemotherapy backbones…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Engineered immune cells take on tough blood cancers
Disease control OngoingThis study tests FDA-approved CAR-T cell therapy in 150 people with certain blood cancers (acute lymphoblastic leukemia or large B-cell lymphoma) that have not responded to standard treatments. Participants receive their own immune cells that have been reprogrammed to attack canc…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New combo therapy aims to halt lymphoma progression
Disease control OngoingThis study compares a new drug combination (glofitamab plus standard Pola-R-CHP) against standard Pola-R-CHP alone in about 1,130 people with untreated large B-cell lymphoma. The main goal is to see if the new combination keeps the cancer from growing longer. Participants must ha…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New hope for aggressive lymphoma: phase 3 trial tests golcadomide combo
Disease control OngoingThis study tests whether adding the experimental drug golcadomide to standard chemotherapy (R-CHOP) works better than chemo alone for people with untreated high-risk large B-cell lymphoma. About 850 participants will receive either the combination or a placebo plus chemo. The mai…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New scan may predict who benefits from CAR T-Cell therapy for lymphoma
Knowledge-focused OngoingThis study tests a new type of PET scan that looks for a protein called PD-L1 in people with large B-cell lymphoma before they receive CAR T-cell therapy. The goal is to see if the scan can help predict who will respond to treatment and tell the difference between active lymphoma…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated May 26, 2026 07:05 UTC